1 Min Read
Merck & Co Inc:
* MERCK’S MAVENCLAD (CLADRIBINE TABLETS) APPROVED FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS IN CANADA Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.